|
1
|
Bray F, Ferlay J, Soerjomataram J, Siegel
RL, Torre LA and Jemal A: Global cancer statistics, 2018 GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cance J Clin. 68:394–424. 2018. View Article : Google Scholar
|
|
2
|
Van Cutsem E and Oliveira J; ESMO
Guidelines Working Group, : Advanced colorectal cancer: ESMO
clinical recommendations for diagnosis, treatment and follow-up.
Ann Oncol. 4 (Suppl):S61–S63. 2009.
|
|
3
|
Goldstein NI, Prewett M, Zuklys K,
Rockwell P and Mendelsohn J: Biological efficacy of a chimeric
antibody to the epidermal growth factor receptor in a human tumor
xenograft model. Clin Cancer Res. 1:1311–1318. 1995.PubMed/NCBI
|
|
4
|
Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ,
Kussie P and Ferguson KM: Structural basis for inhibition of the
epidermal growth factor receptor by cetuximab. Cancer Cell.
7:301–311. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bokemeyer C, Bondarenko I, Hartmann JT, de
Braud F, Schuch G, Zubel A, Celik I, Schlichting M and Koralewski
P: Efficacy according to biomarker status of cetuximab plus
FOLFOX-4 as first-line treatment for metastatic colorectal cancer:
The OPUS study. Ann Oncol. 22:1535–1546. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Van Cutsem E, Kohne CH, Hitre E, Zaluski
J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G,
et al: Cetuximab and chemotherapy as initial treatment for
metastatic colorectal cancer. N Engl J Med. 360:1408–1417. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Corey E, Brown LG, Quinn JE, Poot M,
Roudier MP, Higano CS and Vessella RL: Zoledronic acid exhibits
inhibitory effects on osteoblastic and osteolytic metastases of
prostate cancer. Clin Cancer Res. 9:295–306. 2003.PubMed/NCBI
|
|
8
|
Kato J, Futamura M, Kanematsu M, Gaowa S,
Mori R, Tanahashi T, Matsuhashi N and Yoshida K: Combination
therapy with zoledronic acid and cetuximab effectively suppresses
growth of colorectal cancer cells regardless of KRAS status. Int J
Cancer. 138:1516–1527. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hurwitz H, Fehrenbacher L, Novotny W,
Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S,
Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and
leucovorin for metastatic colorectal cancer. N Engl J Med.
350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tournigand C, Andre T, Achille E, Lledo G,
Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, et
al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced
colorectal cancer: A randomized GERCOR study. J Clin Oncol.
22:229–237. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cunningham D, Humblet Y, Siena S, Khayat
D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype
C, et al: Cetuximab monotherapy and cetuximab plus irinotecan in
irinotecan-refractory metastatic colorectal cancer. N Engl J Med.
351:337–345. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lewis TS, Shapiro PS and Ahn NG: Signal
transduction through MAP kinase cascades. Adv Cancer Res.
74:49–139. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Han FS, Lin MB, Zhu HY, Chen YQ, Shui W
and Xu JM: Anti-proliferation effect of zoledronic acid on human
colon cancer line SW480. Asian Pac J Trop Med. 9:168–171. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schubbert S, Shannon K and Bollag G:
Hyperactive Ras in developmental disorders and cancer. Nat Rev
Cancer. 7:295–308. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Correale P, Marra M, Remondo C, Migali C,
Misso G, Arcuri FP, Del Vecchio MT, Carducci A, Loiacono L, Tassone
P, et al: Cytotoxic drugs up-regulate epidermal growth factor
receptor (EGFR) expression in colon cancer cells and enhance their
susceptibility to EGFR-targeted antibody-dependent
cell-mediated-cytotoxicity (ADCC). Eur J Cancer. 46:1703–1711.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Maniar A, Zhang X, Lin W, Gastman BR,
Pauza CD, Strome SE and Chapoval AI: Human gammadelta T lymphocytes
induce robust NK cell-mediated antitumor cytotoxicity through CD137
engagement. Blood. 116:1726–1733. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nakamura S, Fukui T, Suzuki S, Takeda H,
Watanabe K and Yoshioka T: Long-term survival after a favorable
response to anti-EGFR antibody plus chemotherapy to treat bone
marrow metastasis: A case report of KRAS-wildtype rectal cancer.
Onco Targets Ther. 10:1143–1147. 2017. View Article : Google Scholar : PubMed/NCBI
|
